Angiotech CE marks HemoStream chronic dialysis catheter
This article was originally published in Clinica
Executive Summary
Angiotech Pharmaceuticals has CE marked its HemoStream chronic dialysis catheter for sale in Europe. The catheter is used for long-term vascular access for haemodialysis, a method of removing waste products from the blood of patients with renal failure. It may also be used for temporary access while more permanent options become ready for use, such as surgically-created arteriovenous fistulas (the preferred access method). HemoStream received US FDA clearance in August 2007. Vancouver, Canada-based Angiotech licensed exclusive worldwide marketing and distribution rights to the catheter from Rex Medical (Conshohocken, Pennsylvania) in April 2007.